The abstract is read at the publisher; the summary is JClub's.
A targeted LC-MS/MS assay for Pseudomonas aeruginosa podovirus LUZ19 quantifies virion signature peptide EVAELDGQELAR, mapping to an empirical 1,314 peptide copies per PFU.
- Why it matters: Plaque assays are laborious, host-dependent, and variable, creating a gap for analytical methods that meet modern drug development needs for phage therapeutics.
- What they did: The study used peptide mapping and multiple reaction monitoring on three independent LC-MS/MS runs, selecting EVAELDGQELAR for quantitation and evaluating calibrator bias and intra-/inter-day precision.
- The result: Weighted Deming regression linked peptide concentrations to plaque-assay titers, producing 1,314 (95% CI: 1,098 to 1,529) peptide copies per PFU and establishing an analytical foundation for full assay validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.